Cancer-Killing virus takes on ovarian cancer in first human trial

NCT ID NCT07211659

Recruiting now Disease control Sponsor: Theolytics Limited Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new treatment called THEO-260, a virus designed to infect and destroy cancer cells. It is given directly into the abdomen to 18 people with advanced ovarian cancer that no longer responds to platinum chemotherapy. The main goals are to find a safe dose and see if the virus shows any signs of fighting the tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: THEO-260 (a virus that targets and kills cancer cells)
What this could lead to: If it works, this could point toward a new treatment option for advanced ovarian cancer that is resistant to standard chemotherapy.
What could go wrong: This is a very early, small Phase 1 trial with only 18 participants. The virus may not shrink tumors or could cause side effects like inflammation or cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIOID FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube endometrioid adenocarcinoma fallopian tube serous adenocarcinoma ovarian cancer ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.